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Activation of the nuclear enzyme poly(ADP-ribose) synthethase (PARS) is important in the cel-
lular response to oxidative stress. During ischemia and reperfusion (I/R) increased free radical 
production leads to DNA breakage that stimulates PARS which in turn results in an energy-con-
suming metabolic cycle and initiation of the apoptotic process. Previous studies have reported 
that PARS inhibition confers protection in various models of I/R-induced cardiovascular damage. 
The purpose of this study was to determine the role of PARS inhibition in I/R-induced injury 
of smooth muscle cells and endothelium in the coronary circulation of the isolated guinea-pig 
heart. Control hearts and those treated with a PARS inhibitor — benzamide (100 µmol L–1), were 
subjected to 30 min of subglobal ischemia and subsequent reperfusion (90 min). To analyze the 
functional integrity of smooth muscle cells and endothelium, one-minute intracoronary infusions 
of endothelium-independent (sodium nitroprusside, NaNP; 3 µmol L–1) and endothelium-depend-
ent (substance P, SP; 10 nmol L–1) vasodilators were used before ischemia and at the reperfusion 
time. The degree of the injury of coronary smooth muscle and endothelial cells induced by I/
R was estimated in terms of diminished vasodilator responses to NaNP (at 55 min and 85 min 
of reperfusion) and to SP (at 70 min of reperfusion), respectively, and expressed as the percent-
age of preischemic response. I/R reduced vasorelaxant responses to both vasodilators by half (to 
54.1 ± 5.1% and to 53.6  ±  4.9% of preischemic value for NaNP at 55 min and 85 min of reperfusion, 
respectively and to 45.9 ± 6.5% for SP at 70 min of reperfusion). PARS inhibition provided com-
plete restoration of vasorelaxation induced by NaNP (107.6 ± 13.3% and 104 ± 14.4% of preischemic 
response at the two time points of reperfusion, respectively). However, there was no effect on 
the SP-induced response (48+12.1% of preischemic response). We conclude that pharmacologi-
cal PARS inhibition with benzamide protects coronary smooth muscle cells but not endothelium 
against I/R-induced reperfusion injury in the coronary circulation of the guinea-pig heart.
Keywords: PARS, I/R-induced reperfusion injury, coronary vessels, endothelium, smooth muscle cells
INTRODUCTION
Poly(ADP-ribose) synthetase (PARS) is one of 
the most abundant enzymes in the eukaryotic cell. 
Its main role is to maintain genomic integrity by 
aiding of damaged DNA. PARS catalyzes the cleav-
age of NAD+ into nicotinamide and ADP-ribose and 
uses the latter for the synthesis of branched nucleic 
acid-like polymers — poly(ADP-ribose) (de Murcia 
et al., 1994; Lindahl et al., 1995). PARS activity play 
role in the regulation of cell replication and differ-
entiation (Tanuma et al., 1978; Bakondi et al., 2002). 
Activated PARS utilizes cellular NAD+ (Jacobson et 
al., 1979) so the level of cellular ATP declines dra-
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matically (Goodwin et al., 1978; Sims et al., 1983) 
and affects cell integrity. Moreover, low level of 
NAD+ inhibits ATP regeneration and blocks reac-
tivation of oxidized glutathione resulting in a lack 
of the main defensive mechanism against ischemic 
injury in the cells. All these changes lead to mas-
sive necrosis of cells subjected to ischemia/reper-
fusion (I/R). It has been shown that I/R stimulates 
generation of oxygen-derived free radicals (Lefer et 
al., 1991), which can damage DNA and over-acti-
vate PARS. Therefore PARS inhibition at I/R should 
limit postischemic cell damage. In fact, many stud-
ies have shown beneficial effects of PARS inhibition 
in oxidative stress-related pathologies (Virag, 2005). 
It was proved that inhibition of PARS activity re-
duces heart damage in different models of ischemic 
cardiovascular injury (Thiemermann et al., 1997; 
Farivar et al., 2005; Nagata et al., 2005). However, 
most in vitro and in vivo studies focused on post-
reperfusion damage of myocardial function (Yama-
zaki et al., 2004). Less is known about the role of 
PARS in the injury of vascular smooth muscle and 
endothelial cells (Mehta et al., 1989; Lefer et al., 
1991). Current observations are not clear. Virag and 
Szabo (2002) showed that PARS inhibition with 3-
aminobenzamide prevented the vasospasm caused 
by subarachnoid haemorrhage and improved vas-
cular function in diabetes. Improved recovery of 
endothelial function was shown in pulmonary and 
splanchnic arteries in rats (Nagata et al., 2005). On 
the other hand, Szabo group revealed in many 
studies that inhibition of PARS only partially pro-
tected vascular smooth muscle or endothelial cells 
exposed to various models of oxidative-related in-
jury (Szabo et al., 1996; 2004b; Andrasi et al., 2005). 
Therefore the aim of the present study was to de-
termine if PARS inhibition with benzamide reduces 
to the same degree I/R-induced injury of vascular 
smooth muscle cells and endothelium in the coro-
nary circulation of the isolated guinea-pig heart.
MATERIALS AND METHODS
Chemicals. Acetylcholine (Ach), substance 
P (SP) and sodium nitroprusside (NaNP) were ob-
tained from Sigma Chemical Co. (St. Louis, MO, 
USA). Benzamide was received as a kind gift from 
Professor Thiemermann (The William Harvey Re-
search Institute, London, England).
Perfusion of the isolated guinea-pig heart. 
The method was described in details previously 
(Chlopicki & Gryglewski, 1993). Briefly, guinea-pig 
hearts were inversely perfused through the ascend-
ing aorta according to the Langendorff technique 
(Hugo Sachs Elektronik, HSE) with the Krebs–Hense-
leit buffer of the following composition (mmol L–1): 
KCl 4.7, NaCl 118, CaCl2 2.52, MgSO4 1.64, NaHCO3 
24.88, KH2PO4 1.18, glucose 5.55, sodium pyruvate 
2.0, equilibrated with 95% O2 + 5% CO2 at 37oC. The 
heart was paced at 273 impulses per minute through 
platinum electrodes inserted to the right atrium. 
Left ventricular pressure (LVP) was measured using 
a fluid-filled balloon inserted into the left ventricle 
and connected to a pressure transducer (Isotec HSE). 
Heart systolic contractility was calculated from the 
LVP signal by an analogue differentiation amplifier 
(DIF module, HSE). Coronary flow was monitored 
by Narcomatic Electronic Flowmeter (HSE). All pa-
rameters were continuously displayed throughout 
the experiment and then analysed by a dedicated 
software (PSCF-IGEL, Poland). All experiments were 
completed in less than three hours.
Experimental protocol. Hearts were equili-
brated at the perfusion pressure of 50 mm Hg for 
10 min and then the pressure was raised to 60 mm 
Hg. The hearts were used for the experiment only if 
basal coronary flow was higher than 5 ml min–1 and 
bolus injection of acetylcholine (Ach, 300 pmoles) in-
creased the flow by at least 3 ml min–1.
Coronary vessels were tested for endothelium-
dependent vasorelaxant responses with one-minute 
intracoronary infusions of substance P (SP, 10 nmol 
L–1) and for endothelium-independent vasorelax-
ant responses with sodium nitroprusside (NaNP, 
3 µmol L–1). 
Next, the hearts were subjected to 30 min of 
subglobal ischemia (90–95% reduction in coronary 
flow) followed by a 90 min reperfusion during 
which the vasodilator responses were tested again. 
NaNP was infused at 55 min and 85 min of reper-
fusion. SP as endothelium-dependent vasodilator 
was administered only once during reperfusion 
(at 70 min) because its repetitive administration 
(in time intervals shorter than 15 min) leads to a 
decrease in vasorelaxant responses (tachyphylax-
is). The magnitude of all vascular responses was 
calculated as the area under the curve of coronary 
flow.
Control hearts were compared with hearts 
perfused with Krebs buffer containing benzamide 
(100 µmol L–1) from the beginning of the experi-
ment. The time schedule of I/R was established on 
the basis of previous experiments to obtain selective 
impairment of the response of coronary vessels to 
vasoactive substances with a relatively small effect 
on the basal coronary flow and heart contractility. 
In additional series of experiments the effect of ben-
zamide (100 µmol L–1) on basal hemodynamic func-
tions and vasorelaxant responses was checked.
The investigation conforms to the Guide for 
the Care and Use of Laboratory Animals published 
by the US National Institutes of Health and the ex-
perimental procedure used in the present study 
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was approved by the Jagiellonian University Ethical 
Committee.
Statistics. Changes in vasodilator responses 
are shown as the percentage of basal preischemic 
values. Statistical significance between groups was 
evaluated by unpaired Student’s t-test and within 
the group by paired t-test.
RESULTS
Basal coronary flow was 6.12 ± 0.78 ml min–1 
and heart systolic contractility was 1021 ± 93 mm 
Hg s–1 (n = 10). 
Benzamide at a concentration of 100 µmol 
L–1 did not affect cardiac functions significantly. Af-
ter a 30 min perfusion with benzamide, the basal 
coronary flow and heart systolic contractility were 
reduced by 6–7% (Table 1). Treatment with benza-
mide also did not change the vasodilator responses 
significantly. Vasodilatation caused by substance P 
(SP) was slightly higher (from 10% to 3% after 30 
and 90 min, respectively) and by sodium nitroprus-
side (NaNP) smaller (from 10% to 4% after 30 and 
90 min, respectively) in the presence of PARS inhibi-
tor (Fig. 1).
Ischemia and subsequent reperfusion slightly, 
non-significantly, decreased coronary flow and heart 
systolic contractility. A thirty-minute ischemia and 
45 min of reperfusion decreased coronary flow by 
8% (ns) and heart systolic contractility by 5% (ns) as 
compared to basal values. A similar degree of im-
pairment of coronary flow and heart systolic con-
tractility was observed at the end of the reperfusion. 
In benzamide-treated hearts these values were al-
most identical (Table 1).
The effect of I/R on coronary vessel function 
was much more pronounced. I/R reduced endothe-
lium-independent coronary responses to NaNP ap-
proximately by half, i.e. to 54.1 ± 5.1% (P < 0.001) and 
to 53.6  ±  4.9% (P < 0.001) of preischemic values, at 55 
min and 85 min of reperfusion, respectively. Simi-
larly, the endothelium-dependent vasodilator re-
Table 1. Effect of 30 min ischemia and 90 min of reperfusion (I/R) on coronary flow and heart systolic contractility of 
isolated guinea-pig heart.
Treatment with benzamide (100 µmol L–1) did not affect listed parameters significantly (n = 10).
Parameter Time point
Basal Treatment with 
benzamide (30 min)
I/R 
(45 min)
I/R 
(90 min)
I/R 
(45 min) + 
Benzamide
I/R 
(90 min) + 
Benzamide
Coronary Flow
(ml min–1)
6.12 ± 0.7 5.75 ± 0.92 5.63 ± 0.87 5.85 ± 0.9 5.81 ± 1.02 6.03 ± 0.99
Heart systolic contractility
(mm Hg s–1)
1021 ± 93 949.5 ± 95 969.9+91 991 ± 85 1006 ± 106 998 ± 103
Figure 1. Effects of 90 min perfusion with benzamide 
(100 µmol L–1) on coronary vessel responses to endothe-
lium-dependent (substance P, SP) and endothelium-in-
dependent (sodium nitroprusside, NaNP) vasodilators in 
isolated perfused guinea-pig hearts.
Data expressed as percentage of control response. Open 
columns, vasodilatation evoked by SP (10 nmol L–1); filled 
columns, vasodilatation evoked by NaNP (3 µmol L–1), 
(n = 10).
Figure 2. Effects of benzamide (100 µmol L–1) on coro-
nary vessel responses to endothelium-dependent (sub-
stance P, SP, 10 nmol L–1) and endothelium-independent 
(sodium nitroprusside, NaNP, 3 µmol L–1) vasodilators in 
isolated, perfused guinea-pig hearts subjected to 30 min 
subglobal ischemia and 90 min reperfusion.
Data expressed as percentage of preischemic response. 
Open columns, control hearts; filled columns, hearts treat-
ed with benzamide. (*P < 0.005 between groups; n = 10).
202            2007A. Jakubowski and M. Lomnicka
sponse to SP was depressed to 45.9 ± 6.5% (P < 0.001) 
at 70 min of reperfusion.
PARS inhibition protected the function of 
smooth muscle but not of the endothelial cells of 
coronary vessels against I/R-induced reperfusion in-
jury. The suppression of endothelium-independent 
vascular responses to NaNP was totally reversed 
in benzamide-treated hearts. In this group, the in-
crease in coronary flow reached 107.6 ± 13.3% and 
104.0 ± 14.4% of preischemic values at 55 and 85 min 
of reperfusion, respectively (P < 0.005 vs non-treated 
hearts). In contrast, the I/R-induced suppression of 
endothelium-dependent vasodilator responses to SP 
remained reduced to 48.0 ± 12.1% of the preischemic 
value (ns vs non-treated group) (Fig. 2).
DISCUSSION
Although numerous studies describe the role 
of PARS activation in cell injury, only few investi-
gated the effects of PARS activation in coronary cir-
culation (Gilad et al., 1997).
In the present study we demonstrated that 
benzamide, a well known PARS inhibitor which is 
three times more potent than the widely used 3-ami-
nobenzamide, protected smooth muscle but not en-
dothelial cells against I/R-induced injury of coronary 
vessels in the isolated guinea-pig heart. Inhibition 
of PARS activity did not affect significantly basal 
vascular tone or heart contractility. This is consist-
ent with the PARS mode of action where at normal 
conditions the activity of this enzyme is rather low. 
However, it has been shown that DNA damage that 
occurs even after 15 min of ischemia and subsequent 
reperfusion increases PARS activity up to 500 times 
(D’Amours et al., 1999; Virag & Szabo, 2002). This 
results in a dramatic increase in ATP consumption 
and impairment of mitochondrial respiration leading 
to severe cell damage. PARS activation in cultured 
endothelial cells in response to oxidative stress was 
described for the first time by Junod (Junod et al., 
1989). Additionally, it was shown that at the time 
of I/R smooth muscle and endothelial cells produce 
free radicals causing strong oxidative damage (Virag 
& Szabo, 2002). Our experiments showed that I/R 
led to significant impairment of coronary responses 
to both endothelium-dependent (SP) and endothe-
lium-independent (NaNP) vasodilators. Because the 
over-activation of PARS has been shown in isolated 
heart models (Szabados et al., 2000; Virag & Szabo, 
2002), the use of benzamide should provide reason-
able protection of the examined vascular bed. In 
fact, in our hands, benzamide totally reversed the 
damage of smooth muscle cells but failed to protect 
endothelial cells. Our observations are in accord-
ance with the studies by Szabo (Szabo et al., 2004a; 
2004b) who showed that profound endothelial dys-
function was only partially reversed by PARS inhi-
bition while vasodilator responses of smooth muscle 
cells were totally restored. On the other hand, many 
authors showed complete or at least significant pro-
tection also of endothelial cells by chronic or acute 
PARS inhibition in different vascular beds (Soriano 
et al., 2001; Szabo et al., 2002; Benko et al., 2004). 
This discrepancy shows that the effects of 
PARS inhibition are difficult to predict and strong-
ly depend on the experimental model used, animal 
species as well as the inhibitor. Weaker or slower re-
covery of endothelial function after PARS inhibition 
(Szabo et al., 1998b; 1998a) indicates that the coro-
nary endothelium is more vulnerable to I/R-induced 
injury than other cells (Szabo et al., 2002; 2004b; 
Pacher et al., 2004). Indeed, Mizuno et al. (1997) dem-
onstrated that after normothermic I/R-induced injury 
of pig heart, myocardial and endothelial function 
could be diversified: although the myocardial func-
tion showed a full recovery, the endothelial func-
tion remained impaired. Sack and coworkers (1997) 
showed, in human transplant biopsy specimens, that 
whereas myocyte integrity recovered within 60 min 
of reperfusion, regeneration of the endothelium last-
ed for up to a week.
Another possible explanation of the weaker 
protective effect of PARS inhibition in endothelial 
cells is only partial participation of PARS in the I/
R-induced injury of these cells. Indeed, ATP level 
may not be the only one factor responsible for the 
impairment of endothelial-dependent response in 
reperfusion period. It was shown that PARS activa-
tion contributed to the expression of adhesive mole-
cules like P-selectin and ICAM-1 in hearts subjected 
to global I/R, resulting in neutrophil activation and 
recruitment into the jeopardized tissue (Jerome et al., 
1993; Weyrich et al., 1993; Gilad et al., 1997), which 
is one of the crucial events for I/R injury. Inhibition 
of PARS activity in blood-perfused models may ad-
ditionally prevent the critical neutrophil-endothe-
lium interaction, which in turn leads to a stronger 
protection of these cells, while in our leukocyte-free 
model, this component of the beneficial effects was 
eliminated. 
We did not study here the exact mechanisms 
of the beneficial role of PARS inhibition in the I/R-
induced injury of the coronary vascular bed. How-
ever, the role of PARS over-activation in disruption 
of general cellular energetics is well established.
In summary, we showed that a PARS inhibi-
tor — benzamide provided significant protection of 
smooth muscle but not of endothelial cells against 
I/R-induced injury in the coronary circulation of the 
isolated guinea-pig heart. Further studies are neces-
sary to explain the mechanism of this phenomenon, 
and its relation to PARS inhibition. 
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